These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

737 related articles for article (PubMed ID: 27687869)

  • 1. Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes.
    Sharma P; Shinde SS; Damlaj M; Hefazi Rorghabeh M; Hashmi SK; Litzow MR; Hogan WJ; Gangat N; Elliott MA; Al-Kali A; Tefferi A; Patnaik MM
    Leuk Lymphoma; 2017 Apr; 58(4):872-881. PubMed ID: 27687869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia.
    Kröger N; Eikema DJ; Köster L; Beelen D; de Wreede LC; Finke J; Koenecke C; Niederwieser D; Bornhäuser M; Schoenland S; Potter V; Wolschke C; Maertens J; Theobald M; Kobbe G; Itälä-Remes M; Wulf G; Kahls P; Forcade E; Greinix H; Masszi T; Yakoub-Agha I; Chalandon Y; Robin M;
    Br J Haematol; 2019 May; 185(4):725-732. PubMed ID: 30820933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conditioning Regimen of 5-Day Decitabine Administration for Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Myeloproliferative Neoplasms.
    Cao YG; He Y; Zhang SD; Liu ZX; Zhai WH; Ma QL; Pang AM; Wei JL; Yang DL; Huang Y; Feng SZ; Jiang EL; Han MZ
    Biol Blood Marrow Transplant; 2020 Feb; 26(2):285-291. PubMed ID: 31494229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of the efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome with blastomycosis and survival comparison of different subtypes after the WHO 2022 reclassification].
    Wang H; Ma RZ; Pang AM; Yang DL; Chen X; Zhang RL; Wei JL; Ma QL; Zhai WH; He Y; Jiang EL; Han MZ; Feng SZ
    Zhonghua Xue Ye Xue Za Zhi; 2024 May; 45(5):445-452. PubMed ID: 38964918
    [No Abstract]   [Full Text] [Related]  

  • 6. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.
    Laport GG; Sandmaier BM; Storer BE; Scott BL; Stuart MJ; Lange T; Maris MB; Agura ED; Chauncey TR; Wong RM; Forman SJ; Petersen FB; Wade JC; Epner E; Bruno B; Bethge WA; Curtin PT; Maloney DG; Blume KG; Storb RF
    Biol Blood Marrow Transplant; 2008 Feb; 14(2):246-55. PubMed ID: 18215785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
    Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage allogeneic stem cell transplantation in patients with pediatric myelodysplastic syndrome and myeloproliferative neoplasms.
    Kato M; Yoshida N; Inagaki J; Maeba H; Kudo K; Cho Y; Kurosawa H; Okimoto Y; Tauchi H; Yabe H; Sawada A; Kato K; Atsuta Y; Watanabe K
    Pediatr Blood Cancer; 2014 Oct; 61(10):1860-6. PubMed ID: 24976435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
    Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
    Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of non-myeloablative and reduced-intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromes.
    Jentzsch M; Döhring C; Linke R; Hille A; Grimm J; Pönisch W; Vucinic V; Franke GN; Behre G; Niederwieser D; Schwind S
    Am J Hematol; 2019 Dec; 94(12):1344-1352. PubMed ID: 31495933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic/Myeloproliferative Neoplasms-Unclassifiable: A Retrospective Nationwide Study of the Japan Society for Hematopoietic Cell Transplantation.
    Kurosawa S; Shimomura Y; Tachibana T; Ishiyama K; Ota S; Kobayashi T; Uchida N; Fukushima K; Ashida T; Matsuoka KI; Kanda J; Ichinohe T; Atsuta Y; Murata M; Aoki J
    Biol Blood Marrow Transplant; 2020 Sep; 26(9):1607-1611. PubMed ID: 32454216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical efficacy of allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome-evolved acute myeloid leukemia].
    Chen SL; Shi YY; Zhang LN; Gong M; Zhang XY; Zhao XL; Hao MZ; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
    Zhonghua Xue Ye Xue Za Zhi; 2024 Apr; 45(4):364-369. PubMed ID: 38951064
    [No Abstract]   [Full Text] [Related]  

  • 14. Allogeneic hematopoietic stem cell transplantation in pediatric myelodysplastic syndromes: a multicenter experience from Argentina.
    Basquiera AL; Pizzi S; Correas AG; Longo PG; Goldman WC; Prates MV; Formisano S; Kusminisky G; Feldman L; Berretta AR; García JJ; Staciuk R
    Pediatr Blood Cancer; 2015 Jan; 62(1):153-7. PubMed ID: 25264233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect and safety of 10-day decitabine-containing conditioning regimen for allogeneic hematopoietic stem cell transplantation in 31 patients with acute myeloid leukemia/myelodysplastic syndrome].
    Liu J; Cao YG; Zhang RL; Zhai WH; Chen X; Ma QL; Pang AM; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):472-478. PubMed ID: 37550202
    [No Abstract]   [Full Text] [Related]  

  • 16. [Allo-HSCT for acute myeloid leukemia with myelodysplastic-related changes: a clinical analysis].
    Zhang HX; Pang AM; Chen X; Zhang RL; Zhai WH; Ma QL; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
    Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):814-822. PubMed ID: 34788920
    [No Abstract]   [Full Text] [Related]  

  • 17. Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.
    Benjamin J; Chhabra S; Kohrt HE; Lavori P; Laport GG; Arai S; Johnston L; Miklos DB; Shizuru JA; Weng WK; Negrin RS; Lowsky R
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):837-43. PubMed ID: 24607552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis.
    Cho C; Hsu M; Barba P; Maloy MA; Avecilla ST; Barker JN; Castro-Malaspina H; Giralt SA; Jakubowski AA; Koehne G; Meagher RC; O'Reilly RJ; Papadopoulos EB; Ponce DM; Tamari R; van den Brink MRM; Young JW; Devlin SM; Perales MA
    Bone Marrow Transplant; 2017 Dec; 52(12):1629-1636. PubMed ID: 28991247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Kong J; Gao MG; Qin YZ; Wang Y; Yan CH; Sun YQ; Chang YJ; Xu LP; Zhang XH; Liu KY; Huang XJ; Zhao XS
    BMC Cancer; 2022 Jan; 22(1):11. PubMed ID: 34979982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.